The biopharma sector experienced a sharp rise in workforce reductions during the first half of 2025, with 128 reported layoff rounds—32% more than the same period last year. Multiple companies faced operational pressures resulting in repeated staff cuts and company closures. Significant examples include antibody-drug conjugate firm Vincerx Pharma and autoimmune-focused Atara Biotherapeutics. Despite some companies, such as Vor Bio, securing fresh funding to recover, the overall trend reflects ongoing industry headwinds fueled by clinical setbacks, regulatory challenges, and market dynamics.